1. S216: CLINICAL ACTIVITY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE 1, OPEN-LABEL STUDY. (23rd June 2022) Authors: Michot, J.-M.; Chavez, J. C.; Carpio, C; Ferrari, S.; Feldman, T. A.; Morillo, D.; Kuruvilla, J.; Pinto, A.; Ribrag, V.; Bachy, E; Buchholz, T. J.; Carrancio, S.; Chou, W.-C.; Guarinos, C.; Wu, F.; Li, S.; Patah, P.; Pourdehnad, M.; Nastoupil, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL). (17th June 2021) Authors: Morschhauser, F.; Nowakowski, G. S.; Cartron, G.; Kesanakurthy, V.; Gkasiamis, A.; Patah, P.; Delarue, R.; Wang, T.; Li, J.; Xian, D.; Fox, C. P.; Martin, P. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗